A Breakthrough AI Tool for Predicting Breast Cancer Risk
Each year, over 2.3 million women globally are diagnosed with breast cancer, with more than 370,000 cases in the United States alone. Despite advancements, many are still diagnosed late, often without known risk factors.
Clairity Breast: A New Era in Risk Prediction
The FDA has granted De Novo authorization to Clairity Breast, the first AI-powered platform that predicts a woman’s five-year risk of developing breast cancer using only a standard mammogram. Unlike traditional models relying on age or family history, Clairity Breast analyzes mammograms to detect subtle patterns linked to future cancer development.
Transforming Screening Guidelines
Clairity Breast’s analysis revealed that many women in their 40s have breast cancer risk levels comparable to older women. In a study of over 30,000 mammograms:
- 37% of women in their 40s were at intermediate risk
- 16% were at high risk
These findings advocate for a personalized, risk-based screening approach, enabling earlier interventions and more effective care.
Promoting Equity in Care
Clairity Breast addresses critical care gaps by accurately representing diverse racial and ethnic groups, ensuring broader accessibility. It integrates seamlessly into existing workflows, requiring only a standard 2D mammogram without relying on demographic or genetic data.
From Detection to Prevention
Beyond early detection, a high-risk score can prompt supplemental imaging, earlier screenings, and preventive measures. Simultaneously, it spares lower-risk women from unnecessary tests, enhancing both outcomes and cost-efficiency.
Looking Ahead
Clairity Breast is set for a commercial launch in late 2025, initially through a self-pay model. Efforts are underway to secure insurance coverage, making this groundbreaking tool accessible to more women.
By leveraging AI advancements, Clairity Breast promises to revolutionize breast cancer prevention and care, ensuring timely and personalized interventions for women worldwide.
